Last updated on April 24, 2014 at 17:35 EDT

Hydrogel Implant GelrinC Demonstrates Impressive Recovery Rates for Patients with Knee Cartilage Damage

September 16, 2013

Treatment shows potential as a safe and highly effective for articular cartilage injuries

PRINCETON, New Jersey and OR AKIVA, Israel, September 16, 2013 /PRNewswire/ –

Regentis Biomaterials announced today new clinical data demonstrating the efficacy and
safety of its GelrinC implant for treating articular cartilage in injured knees. As
presented at the International Cartilage Repair Society World Congress in Izmir, Turkey,
the clinical results demonstrated sustained knee function improvement over 24 months after
implantation and significant pain reduction. In addition, the clinical safety data showed
that adverse effects were limited and comparable to those reported in similar studies with
no serious adverse events related to the implant.

“These results show that GelrinC is safe and that the treatment effectively
regenerates high quality cartilage,” said Regentis Biomaterials president and CEO Alastair
Clemow. “While recovery rates for knees treated with standard procedures plateau and even
decrease over time, GelrinC patients showed constant improvement over the course of the

Articular cartilage is the smooth, white tissue covering the ends of bones where they
come together to form joints. In the knee, this cartilage can be damaged by a traumatic
sports accident or a bad fall. A painful injury for patients, repairing articular
cartilage is a challenge for doctors to treat since the tissue has no capacity to heal

GelrinC is a biodegradable hydrogel implant designed to treat cartilage defects in the
knee. It is administered as a liquid to fill any shape of cartilage defect and it is then
converted into a solid after 90 seconds of exposure to ultra-violet light. The GelrinC
implant naturally degrades within 6-12 months and is replaced with functional and durable

After two years of study, patients had a substantial improvement of the Knee injury
and Osteoarthritis Outcome Score (KOOS), excluding the sports subscale, of 23.6 points at
18 months, representing a 43% improvement, and 32.9 points at 24 months, representing a
60% improvement (52.6 vs. 84.1). KOOS is a patient-reported outcome measurement instrument
developed to assess a patient’s opinion about their knee and associated problems. Scores
from the international knee documentation committee (IKDC), another measure of patient
progress, were even more impressive. The subjective questionnaire showed an improvement of
86% at 18 months and 94% at 24 months (40.4 vs. 78.4).

“These results are particularly strong when you compare them against those achieved
through standard procedures, such as microfracture, which increase the flow of blood and
bone marrow stem cells to the damaged area,” said Dr. Ron Arbel who will present the
study’s outcome at ICRS 2013 and is a study investigator. “GelrinC works in combination
with the microfracture procedure to greatly enhance the body’s ability to regenerate new
cartilage so that patients can return to an active lifestyle.”

Radiological evaluation by MRI scans demonstrated that newly developed cartilage
structure was similar in its quality to native cartilage. These measurements were obtained
by using traditional techniques and quantitative T2 mapping which evaluate changes in the
quality of the regenerated cartilage.

“MRI evaluations with combined morphologic and biochemical assessment allowed us to
monitor patient progress made with GelrinC,” said University of Vienna medical professor
Dr. Siegfried Trattnig who will present the radiological outcome of the patients at ICRS
2013. “We were able to understand using noninvasive magnetic resonance techniques how new
tissue integrated with the host tissue, as well as the biochemistry behind the repair

The clinical results came from a single-arm, multi-center study that involved 23
patients in Europe and Israel. An additional 30 patients are currently enrolled at 12 new
sites in Germany, Belgium, Poland, the Netherlands and Israel.

CE mark-approved, GelrinC is an investigational device and is not available for sale
in the U.S. and Israel.

About Regentis Biomaterials

With offices in Or Akiva, Israel and Princeton, NJ, Regentis Biomaterials is a
privately held company focused on developing and commercializing proprietary hydrogels for
tissue regeneration. The company’s core technology is a biodegradable hydrogel called
Gelrin(TM). It is based on polyethylene glycol diacrylate and denatured fibrinogen
originally developed at the Technion – Israel Institute of Technology by Prof. Dror
Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a
synthetic material with the bio-functionality of a natural substance for a range of
clinical applications. The company’s flagship product, GelrinC(TM), designed for the
treatment of articular cartilage lesions. For more information, please visit


        For media inquiries, please contact:
        Josh Turner
        Media Relations
        Phone: +1-917-231-0550

SOURCE Regentis Biomaterials Ltd.

Source: PR Newswire